Thyroid nodule medical therapy: Difference between revisions
| Line 9: | Line 9: | ||
==Medical Therapy== | ==Medical Therapy== | ||
The goals of initial therapy of DTC are follows: | |||
* To remove the primary tumor, disease that has extended beyond the thyroid capsule, and involved cervical lymph nodes. Completeness of surgical resection is an important determinant of outcome, while residual metastatic lymph nodes represent the most common site of disease persistence=recurrence | |||
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057; discussion 1057–1058. 117. | |||
Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL 2003 Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 113:2102–2107. 118. | |||
Wang TS, Dubner S, Sznyter LA, Heller KS 2004 Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg 130:110– 113 | |||
* To minimize treatment-related morbidity. The extent of surgery and the experience of the surgeon both play important roles in determining the risk of surgical complications | |||
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228:320–330. 120. | |||
Friedman M, Pacella BL, Jr 1990 Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations. Otolaryngol Clin North Am 23:413–427 | |||
* To permit accurate staging of the disease. Because disease staging can assist with initial prognostication, disease management, and follow-up strategies, accurate postoperative staging is a crucial element in the management of patients with DTC | |||
Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B 1997 A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79:2414–2423. 122. | |||
Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885 | |||
* To facilitate postoperative treatment with radioactive iodine, where appropriate. For patients undergoing RAI remnant ablation, or RAI treatment of residual or metastatic disease, removal of all normal thyroid tissue is an important element of initial surgery . Near total or total thyroidectomy also may reduce the risk for recurrence within the contralateral lobe | |||
Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY 1998 Use of radioactive iodine for thyroid remnant ablation in welldifferentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 21:77–81. | |||
Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB 2001 Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 130:921–930 | |||
* To permit accurate long-term surveillance for disease recurrence. Both RAI whole-body scanning (WBS) and measurement of serum Tg are affected by residual normal thyroid tissue. Where these approaches are utilized for long-term monitoring, near-total or totalthyroidectomy is required | |||
Mazzaferri EL 1999 An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421–427. | |||
* To minimize the risk of disease recurrence and metastatic spread. Adequate surgery is the most important treatment variable influencing prognosis, while radioactive iodine treatment, TSH suppression, and external beam irradiation each play adjunctive roles in at least some patients | |||
Kim TH, Yang DS, Jung KY, Kim CY, Choi MS 2003 Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 55:1006–1012 | |||
It is recommended to use thryoid hormone in iodine insufficient areas as a treatment for benign thyroid nodules. Thyroid hormone in doses that suppress the serum TSH to subnormal levels may result in a decrease in nodule size and may prevent the appearance of new nodules in regions of the world with borderline low iodine intake but in iodine sufficient areas, there are insufficient evidence of beneficial effect of thyroid hormone treatment for benign thyroid nodules | It is recommended to use thryoid hormone in iodine insufficient areas as a treatment for benign thyroid nodules. Thyroid hormone in doses that suppress the serum TSH to subnormal levels may result in a decrease in nodule size and may prevent the appearance of new nodules in regions of the world with borderline low iodine intake but in iodine sufficient areas, there are insufficient evidence of beneficial effect of thyroid hormone treatment for benign thyroid nodules | ||
Revision as of 22:09, 11 August 2017
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
|
Thyroid nodule Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thyroid nodule medical therapy On the Web |
|
American Roentgen Ray Society Images of Thyroid nodule medical therapy |
|
Risk calculators and risk factors for Thyroid nodule medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
The goals of initial therapy of DTC are follows:
- To remove the primary tumor, disease that has extended beyond the thyroid capsule, and involved cervical lymph nodes. Completeness of surgical resection is an important determinant of outcome, while residual metastatic lymph nodes represent the most common site of disease persistence=recurrence
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057; discussion 1057–1058. 117.
Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL 2003 Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 113:2102–2107. 118.
Wang TS, Dubner S, Sznyter LA, Heller KS 2004 Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg 130:110– 113
- To minimize treatment-related morbidity. The extent of surgery and the experience of the surgeon both play important roles in determining the risk of surgical complications
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228:320–330. 120.
Friedman M, Pacella BL, Jr 1990 Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations. Otolaryngol Clin North Am 23:413–427
- To permit accurate staging of the disease. Because disease staging can assist with initial prognostication, disease management, and follow-up strategies, accurate postoperative staging is a crucial element in the management of patients with DTC
Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B 1997 A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 79:2414–2423. 122.
Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885
- To facilitate postoperative treatment with radioactive iodine, where appropriate. For patients undergoing RAI remnant ablation, or RAI treatment of residual or metastatic disease, removal of all normal thyroid tissue is an important element of initial surgery . Near total or total thyroidectomy also may reduce the risk for recurrence within the contralateral lobe
Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY 1998 Use of radioactive iodine for thyroid remnant ablation in welldifferentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 21:77–81.
Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB 2001 Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 130:921–930
- To permit accurate long-term surveillance for disease recurrence. Both RAI whole-body scanning (WBS) and measurement of serum Tg are affected by residual normal thyroid tissue. Where these approaches are utilized for long-term monitoring, near-total or totalthyroidectomy is required
Mazzaferri EL 1999 An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421–427.
- To minimize the risk of disease recurrence and metastatic spread. Adequate surgery is the most important treatment variable influencing prognosis, while radioactive iodine treatment, TSH suppression, and external beam irradiation each play adjunctive roles in at least some patients
Kim TH, Yang DS, Jung KY, Kim CY, Choi MS 2003 Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 55:1006–1012
It is recommended to use thryoid hormone in iodine insufficient areas as a treatment for benign thyroid nodules. Thyroid hormone in doses that suppress the serum TSH to subnormal levels may result in a decrease in nodule size and may prevent the appearance of new nodules in regions of the world with borderline low iodine intake but in iodine sufficient areas, there are insufficient evidence of beneficial effect of thyroid hormone treatment for benign thyroid nodules
In pregnant women with FNA that is suspicious for or diagnostic of PTC, consideration could be given to administration of LT4 therapy to keep the TSH in the range of 0.1–1 mU=L
Kuy S, Roman SA, Desai R, Sosa JA 2009 Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 144:399–406. 109.
Rosen IB, Korman M, Walfish PG 1997 Thyroid nodular disease in pregnancy: current diagnosis and management. Clin Obstet Gynecol 40:81–89